Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Hematological Malignancies
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2149
)
Lymphoma (1208
)
Leukemia (2149
)
Lymphoma (1208
)
›
Associations
(3922)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
lisocabtagene maraleucel
Sensitive: A1 - Approval
lisocabtagene maraleucel
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
gilteritinib
Sensitive: A1 - Approval
gilteritinib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
carfilzomib
Sensitive
:
A1
carfilzomib
Sensitive: A1 - Approval
carfilzomib
Sensitive
:
A1
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
enasidenib
Sensitive: A1 - Approval
enasidenib
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
glasdegib
Sensitive: A1 - Approval
glasdegib
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
bortezomib + panobinostat
Sensitive: A1 - Approval
bortezomib + panobinostat
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
bortezomib + pegylated liposomal doxorubicin
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Lymphoma
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
ibrutinib + rituximab
Sensitive: A1 - Approval
ibrutinib + rituximab
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
azacitidine oral
Sensitive: A1 - Approval
azacitidine oral
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
SVd
Sensitive: A1 - Approval
SVd
Sensitive
:
A1
SVd
Sensitive: A1 - Approval
SVd
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
ciltacabtagene autoleucel
Sensitive: A1 - Approval
ciltacabtagene autoleucel
Sensitive
:
A1
ciltacabtagene autoleucel
Sensitive: A1 - Approval
ciltacabtagene autoleucel
Sensitive
:
A1
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
venetoclax + obinutuzumab
Sensitive: A1 - Approval
venetoclax + obinutuzumab
Sensitive
:
A1
BCR-ABL1 fusion
Chronic Myeloid Leukemia
BCR-ABL1 fusion
Chronic Myeloid Leukemia
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
dasatinib
Sensitive: A1 - Approval
dasatinib
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login